0001193125-21-240435 | 10-Q | XBRL Viewer

Print Document View Excel Document

Cover Page - shares	6 Months Ended
Cover Page - shares	Jun. 30, 2021	Jul. 31, 2021
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Registrant Name	ZAI LAB LIMITED
Entity Central Index Key	0001704292
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Interactive Data Current	Yes
Entity File Number	001-38205
Entity Incorporation, State or Country Code	E9
Entity Address, Address Line One	4560 Jinke Road
Entity Address, Address Line Two	Bldg. 1, Fourth Floor Pudong
Entity Address, City or Town	Shanghai
Entity Address, Country	CN
Entity Address, Postal Zip Code	201210
Document Quarterly Report	true
Document Transition Report	false
Entity Tax Identification Number	98-1144595
Entity Small Business	false
Local Phone Number	6163 2588
City Area Code	86 21
American Depositary Shares
Document Information [Line Items]
Trading Symbol	ZLAB
Entity Common Stock, Shares Outstanding		65,826,281
Title of 12(b) Security	American Depositary Shares, each representing 1 Ordinary Share, par value $0.00006 per share
Security Exchange Name	NASDAQ
Ordinary Shares
Document Information [Line Items]
Trading Symbol	9688
Entity Common Stock, Shares Outstanding		95,408,743
Title of 12(b) Security	Ordinary Shares, par value $0.00006 per share

Consolidated balance sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 1,766,573	$ 442,116
Short-term investments	0	744,676
Accounts receivable	18,029	5,165
Inventories	11,114	13,144
Prepayments and other current assets	12,887	10,935
Total current assets	1,808,603	1,216,036
Restricted cash, non-current	743	743
Investments in equity investees	1,070	1,279
Prepayments for equipment	1,846	274
Property and equipment, net	31,642	29,162
Operating lease right-of-use assets	17,015	17,701
Land use rights, net	7,849	7,908
Intangible assets, net	1,733	1,532
Long term deposits	891	862
Value added tax recoverable	23,823	22,141
Total assets	1,895,215	1,297,638
Current liabilities:
Accounts payable	125,621	62,641
Current operating lease liabilities	6,371	5,206
Other current liabilities	61,925	30,196
Total current liabilities	193,917	98,043
Deferred income	17,632	16,858
Non-current operating lease liabilities	11,968	13,392
Total liabilities	223,517	128,293
Commitments and contingencies
Shareholders' equity
Ordinary shares (par value of $0.00006 per share; 500,000,000 shares authorized, 94,758,189 and 87,811,026 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively)	6	5
Additional paid-in capital	2,799,318	1,897,467
Accumulated deficit	(1,109,837)	(713,603)
Accumulated other comprehensive loss	(16,865)	(14,524)
Treasury Stock	(924)
Total shareholders' equity	1,671,698	1,169,345
Total liabilities and shareholders' equity	$ 1,895,215	$ 1,297,638

Consolidated balance sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 5	$ 1
Ordinary shares, par value	$ 0.00006	$ 0.00006
Ordinary shares, shares authorized	500,000,000	500,000,000
Ordinary shares, shares issued	94,758,189	87,811,026
Ordinary shares, shares outstanding	94,758,189	87,811,026
Treasury Stock, Shares	6,086

Consolidated statements of operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue	$ 36,935	$ 10,995	$ 57,038	$ 19,213
Expenses:
Cost of sales	(10,868)	(2,896)	(18,373)	(4,980)
Research and development	(142,224)	(68,307)	(346,076)	(102,049)
Selling, general and administrative	(54,414)	(23,758)	(90,252)	(42,472)
Loss from operations	(170,571)	(83,966)	(397,663)	(130,288)
Interest income	244	1,227	458	2,882
Interest expenses		(55)		(114)
Other income (expense), net	7,406	2,434	1,179	(691)
Loss before income tax and share of loss from equity method investment	(162,921)	(80,360)	(396,026)	(128,211)
Income tax expense
Share of loss from equity method investment	(403)	(269)	(208)	(406)
Net loss	(163,324)	(80,629)	(396,234)	(128,617)
Net loss attributable to ordinary shareholders	$ (163,324)	$ (80,629)	$ (396,234)	$ (128,617)
Loss per share - basic and diluted	$ (1.76)	$ (1.08)	$ (4.37)	$ (1.74)
Weighted-average shares used in calculating net loss per ordinary share - basic and diluted	93,045,531	74,738,563	90,723,132	73,847,551

Consolidated statements of comprehensive loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (163,324)	$ (80,629)	$ (396,234)	$ (128,617)
Other comprehensive (loss) income, net of tax of nil:
Foreign currency translation adjustments	(5,241)	(1,173)	(2,341)	2,366
Comprehensive loss	$ (168,565)	$ (81,802)	$ (398,575)	$ (126,251)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Consolidated statements of comprehensive loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statement of Comprehensive Income [Abstract]
Other comprehensive income, tax	$ 0	$ 0	$ 0	$ 0

- Definition

Amount of tax expense (benefit) allocated to other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e39076-109324

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

Consolidated statements of shareholders' equity - USD ($) $ in Thousands	Total	Ordinary Shares	Additional Paid In Capital	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income	Treasury Stock
Balance at Dec. 31, 2019	$ 294,660	$ 4	$ 734,734	$ (444,698)	$ 4,620
Balance, Shares at Dec. 31, 2019		68,237,247
Issuance of ordinary shares upon vesting of restricted shares	0	$ 0	0
Issuance of ordinary shares upon vesting of restricted shares, Shares		80,200
Exercise of shares option	346	$ 0	346
Exercise of shares option, Shares		49,278
Issuance of ordinary shares upon follow-on public offering, net of issuance cost	280,568	$ 0	280,568
Issuance of ordinary shares upon follow-on public offering, net of issuance cost, Shares		6,300,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	(740)
Share-based compensation	6,463		6,463
Net loss	(47,988)			(47,988)
Foreign currency translation	3,539				3,539
Balance at Mar. 31, 2020	537,588	$ 4	1,022,111	(492,686)	8,159
Balance, Shares at Mar. 31, 2020		74,666,725
Balance at Dec. 31, 2019	294,660	$ 4	734,734	(444,698)	4,620
Balance, Shares at Dec. 31, 2019		68,237,247
Net loss	(128,617)
Foreign currency translation	2,366
Balance at Jun. 30, 2020	465,466	$ 4	1,031,791	(573,315)	6,986
Balance, Shares at Jun. 30, 2020		74,882,338
Balance at Mar. 31, 2020	537,588	$ 4	1,022,111	(492,686)	8,159
Balance, Shares at Mar. 31, 2020		74,666,725
Issuance of ordinary shares upon vesting of restricted shares	0	$ 0	0
Issuance of ordinary shares upon vesting of restricted shares, Shares		36,000
Exercise of shares option	2,729	$ 0	2,729
Exercise of shares option, Shares		179,613
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	(13)		(13)
Share-based compensation	6,964		6,964
Net loss	(80,629)			(80,629)
Foreign currency translation	(1,173)				(1,173)
Balance at Jun. 30, 2020	465,466	$ 4	1,031,791	(573,315)	6,986
Balance, Shares at Jun. 30, 2020		74,882,338
Balance at Dec. 31, 2020	$ 1,169,345	$ 5	1,897,467	(713,603)	(14,524)
Balance, Shares at Dec. 31, 2020	87,811,026	87,811,026
Issuance of ordinary shares upon vesting of restricted shares	$ 0	$ 0	0
Issuance of ordinary shares upon vesting of restricted shares, Shares		81,600
Exercise of shares option	702	$ 0	702
Exercise of shares option, Shares		58,364
Issuance of ordinary shares in connection with collaboration and license arrangement	62,250	$ 0	62,250
Issuance of ordinary shares in connection with collaboration and license arrangement, Shares		568,182
Issuance cost adjustment for secondary listing	65		65
Share-based compensation	7,318		7,318
Net loss	(232,910)			(232,910)
Foreign currency translation	2,900				2,900
Balance at Mar. 31, 2021	1,009,670	$ 5	1,967,802	(946,513)	(11,624)
Balance, Shares at Mar. 31, 2021		88,519,172
Balance at Dec. 31, 2020	$ 1,169,345	$ 5	1,897,467	(713,603)	(14,524)
Balance, Shares at Dec. 31, 2020	87,811,026	87,811,026
Net loss	$ (396,234)
Foreign currency translation	(2,341)
Balance at Jun. 30, 2021	$ 1,671,698	$ 6	2,799,318	(1,109,837)	(16,865)	$ (924)
Balance, Shares at Jun. 30, 2021	94,758,189	94,758,189				(6,086)
Balance at Mar. 31, 2021	$ 1,009,670	$ 5	1,967,802	(946,513)	(11,624)
Balance, Shares at Mar. 31, 2021		88,519,172
Issuance of ordinary shares upon vesting of restricted shares	0	$ 0	0
Issuance of ordinary shares upon vesting of restricted shares, Shares		32,100
Exercise of shares option	3,289	$ 0	3,289
Exercise of shares option, Shares		490,517
Receipt of employees' shares to satisfy tax withholding obligations related to share-based compensation						(6,086)
Receipt of employees' shares to satisfy tax withholding obligations related to share-based compensation	(924)					$ (924)
Issuance of ordinary shares upon follow-on public offering, net of issuance cost	817,996	$ 1	817,995
Issuance of ordinary shares upon follow-on public offering, net of issuance cost, Shares		5,716,400
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	(879)
Share-based compensation	10,232		10,232
Net loss	(163,324)			(163,324)
Foreign currency translation	(5,241)				(5,241)
Balance at Jun. 30, 2021	$ 1,671,698	$ 6	$ 2,799,318	$ (1,109,837)	$ (16,865)	$ (924)
Balance, Shares at Jun. 30, 2021	94,758,189	94,758,189				(6,086)

Consolidated statements of shareholders' equity (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2020
Share issuance cost upon follow-on public offering	$ 879	$ 13	$ 740

Consolidated statements of cash flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating activities
Net loss	$ (396,234)	$ (128,617)
Adjustments to reconcile net loss to net cash used in operating activities:
Allowance for doubtful accounts	4	2
Inventory write-down	290	7
Depreciation and amortization expenses	2,975	2,107
Amortization of deferred income	(156)	(156)
Share-based compensation	17,550	13,427
Noncash research and development expenses	62,250
Share of loss from equity method investment	208	406
Loss on disposal of property and equipment	4	1
Noncash lease expenses	2,779	2,114
Changes in operating assets and liabilities:
Accounts receivable	(12,868)	(3,235)
Inventories	1,740	(571)
Prepayments and other current assets	(1,952)	(948)
Long term deposits	(29)	(335)
Value added tax recoverable	(1,682)	(2,422)
Accounts payable	62,980	9,732
Other current liabilities	28,077	4,697
Operating lease liabilities	(2,214)	(1,539)
Deferred income	930	13,011
Net cash used in operating activities	(235,348)	(92,319)
Cash flows from investing activities:
Purchases of short-term investments		(205,000)
Proceeds from maturity of short-term investments	743,902	200,000
Purchase of property and equipment	(5,647)	(1,303)
Purchase of intangible assets	(427)	(218)
Net cash provided by (used in) investing activities	737,828	(6,521)
Cash flows from financing activities:
Repayment of short-term borrowings		(2,130)
Proceeds from exercises of stock options	3,992	3,075
Proceeds from issuance of ordinary shares upon public offerings	818,874	281,295
Payment of public offering costs	(1,323)	(740)
Employee taxes paid related to net share settlement of equity awards	(594)
Net cash provided by financing activities	820,949	281,500
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	1,028	12
Net increase in cash, cash equivalents and restricted cash	1,324,457	182,672
Cash, cash equivalents and restricted cash - beginning of period	442,859	76,442
Cash, cash equivalents and restricted cash - end of period	1,767,316	259,114
Supplemental disclosure on non-cash investing and financing activities:
Payables for purchase of property and equipment	1,720	984
Payables for intangible assets	58
Payables for public offering costs	555
Supplemental disclosure of cash flow information:
Cash and cash equivalents	1,766,573	258,604
Restricted cash, non-current	743	510
Total cash and cash equivalents and restricted cash	$ 1,767,316	259,114
Interest paid		$ 122

Organization and principal activities	6 Months Ended
Organization and principal activities	Jun. 30, 2021
Organization and principal activities
Organization and Principal Activities	1. Organization and principal activities Zai Lab Limited (the “Company”) was incorporated on March 28, 2013 in the Cayman Islands as an exempted company with limited liability under the Companies Law of the Cayman Islands. The Company and its subsidiaries (collectively referred to as the “Group”) are focused on developing and commercializing therapies that address medical conditions with unmet medical needs including, in particular, oncology, autoimmune disorders and infectious diseases. The Group’s principal operations and geographic markets are in mainland China (hereinafter referred to as “China”), Hong Kong, Macau and Taiwan (hereinafter collectively referred to as “Greater China”). The Group has a substantial presence in Greater China and the United States .

Basis of presentation and consolidation and significant accounting policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of presentation and consolidation and significant accounting policies	2. Basis of presentation and consolidation and significant accounting policies (a) Basis of presentation The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company’s financial position, results of operations, and cash flows in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company’s unaudited condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December 31, 2020 condensed consolidated balance sheets data were derived from audited financial statements, but do not include all disclosures required by U.S. GAAP. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. (b) Principles of consolidation The unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All intercompany transactions and balances among the Company and its subsidiaries are eliminated upon consolidation. (c) Use of estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating the current expected credit losses for financial assets, assessing the impairment of long-lived assets, discount rate of operating lease liabilities, revenue recognition, allocation of the research and development service expenses to the appropriate financial reporting period based on the progress of the research and development projects, share-based compensation expenses, recoverability of deferred tax assets and a lack of marketability discount of the ordinary shares issued in connection with collaboration and license arrangement (Note 15 ). Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates. (d) Fair value measurements The Group applies ASC topic 820 (“ASC 820”), Fair Value Measurements and Disclosures , in measuring fair value. ASC 820 defines fair value, establishes a framework for measuring fair value and requires disclosures to be provided on fair value measurement. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - Include other inputs that are directly or indirectly observable in the marketplace. Level 3 - Unobservable inputs which are supported by little or no market activity. ASC 820 describes three main approaches to measur e the fair value of assets and liabilities: (1) market approach; (2) income approach and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset. Financial instruments of the Group primarily include cash, cash equivalents and restricted cash, short-term investments, accounts receivable, prepayments and other current assets, accounts payable and other payables. As of June 30, 2021 and December 31, 2020, the carrying values of cash and cash equivalents, short-term investments, accounts receivable, prepayments and other current assets, accounts payable and other payable approximated their fair values due to the short-term maturity of these instruments, and the carrying value of restricted cash approximates its fair value based on the nature of the assessment of the ability to recover these amounts. (e) Recent accounting pronouncements Adopted Accounting Standards In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . This update simplifies the accounting for income taxes as part of the FASB’s overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC 740, Income taxes , and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in fiscal years beginning after December 15, 2020, and interim periods therein, and early adoption is permitted. Certain amendments in this update should be applied retrospectively or modified retrospectively, all other amendments should be applied prospectively. The Group adopted this standard on January 1, 2021. There was no material impact to the Group’s financial position or results of operations upon adoption. (f) Significant accounting policies For a more complete discussion of the Company’s significant accounting policies and other information, the unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Cash and cash equivalents

6 Months Ended

Jun. 30, 2021

Cash and Cash Equivalents [Abstract]

Cash and cash equivalents

3. Cash and cash equivalents


	As of
	June 30, 2021		December 31, 2020
	$		$
Cash at bank and in hand		1,465,757		441,283
Cash equivalents (note (i))		300,816		833

		1,766,573		442,116

Denominated in:
US$		907,662		297,813
RMB (note (ii))		36,222		23,898
Hong Kong dollar (“HK$”)		822,182		119,695
Australian dollar (“A$”)		471		710
Taiwan dollar (“TW$”)		36		—

		1,766,573		442,116

Note:

(i)	Cash equivalents represent short-term and highly liquid investments in a money market fund.

(ii)	Certain cash and bank balances denominated in RMB were deposited with banks in China. The conversion of these RMB denominated balances into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the government of the People’s Republic of China (“PRC”).

Restricted cash, non-current	6 Months Ended
Restricted cash, non-current	Jun. 30, 2021
Restricted Cash [Abstract]
Restricted cash, non-current	4. Restricted cash, non-current The Group’s restricted cash balance of $743 and $743 as of June 30, 2021 and December 31, 2020, respectively, was long-term bank deposits held as collateral for issuance of letters of credit. These deposits will be released when the related letters of credit are settled by the Group.

Short-term investments	6 Months Ended
Short-term investments	Jun. 30, 2021
Short-term investments
Short-term investments	5. Short-term investments Short-term investments are primarily comprised of time deposits with original maturities between three months and one year. As of June 30, 2021, the Group held no short-term investments. As of December 31, 2020, the Group’s short-term investments consisted entirely of short-term held to maturity debt instruments with high credit ratings, which were determined to have remote risk of expected credit loss. Accordingly, no allowance for credit loss was recorded as of December 31, 2020.

Inventories

6 Months Ended

Jun. 30, 2021

Inventories

Inventories

6. Inventories

The Group’s inventory balance of $11,114 and $13,144 as of June 30, 2021 and December 31, 2020,

respectively, mainly consisted of finished goods purchased from Tesaro, Inc., now GlaxoSmithKline (GSK), for distribution in Hong Kong, and from NovoCure Limited (“Novocure”) and Deciphera Pharmaceuticals, LLC (“Deciphera”) for distribution in Hong Kong and China, as well as finished goods, work in process and certain raw materials for ZEJULA commercialization in China.


	As of
	June 30, 2021		December 31, 2020
	$		$
Finished goods		4,477		3,041
Raw materials		6,269		10,103
Work in process		368		—

Inventories		11,114		13,144

The Group writes down inventory for any excess or obsolete inventories or when the Group believes that the net realizable value of inventories is less than the carrying value. During the three and six months ended June 30, 2021, the Group recorded

write-downs

of $277 and $290, respectively, in cost of revenues. During the three months and six months ended June 30, 2020, the Group recorded

write-downs

of $7 and $7, respectively, in cost of revenues.

Investments in Equity Investees	6 Months Ended
Investments in Equity Investees	Jun. 30, 2021
Investments in equity investees
Investments in equity investees	7. Investments in equity investees In June 2017, the Group entered into an agreement with three third parties to launch JING Medicine Technology (Shanghai) Ltd. (“JING”), an entity which provides services for product discovery and development, consultation and transfer of pharmaceutical technology. The capital contribution by the Group was RMB26,250 in cash, which was paid by the Group in 2017 and 2018, representing 20% and 18% of the equity interest of JING as of December 31, 2020 and June 30, 2021, respectively . The Group accounts for this investment using the equity method of accounting due to the fact that the Group can exercise significant influence on the investee. The Group recorded its gain on deemed disposal in this investee of nil and $ 463 for the three months and six months ended June 30, 2021, and recorded loss of $ 403 and $ 671 for its portion of JING’s net loss for the three months and six months ended June 30, 2021, respectively. The Group recorded share of loss in this investee of $269 and $ 406 for the three and six months ended June 30, 2020, respectively.

Property and Equipment, net

6 Months Ended

Jun. 30, 2021

Property and equipment, net

Property and equipment, net

8. Property and equipment, net

Property and equipment consist of the following:


	As of
	June 30, 2021			December 31, 2020
	$			$
Office equipment		444			430
Electronic equipment		3,269			2,646
Vehicle		218			143
Laboratory equipment		13,384			11,933
Manufacturing equipment		12,838			12,198
Leasehold improvements		9,889			9,641
Construction in progress		4,699			2,423

		44,741			39,414
Less: accumulated depreciation		(13,099	)		(10,252	)

Property and equipment, net		31,642			29,162

Depreciation expenses for the three and six months ended June 30, 2021 were $1,407 and $2,747, respectively. Depreciation expenses for the three and six months ended June 30, 2020 were $968 and $1,974, respectively.

Revenue

6 Months Ended

Jun. 30, 2021

Revenue

Revenue

9. Revenue

he Group’s revenue is derived from the sale of ZEJULA, Optune and QINLOCK in China and Hong Kong. The table below presents the Group’s net product sales for the three and six months ended June 30, 2021 and 2020.


	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
	$			$			$			$
Product revenue - gross		41,380			11,478			87,935			20,415
Less: Rebate and sales return		(4,445	)		(483	)		(30,897	)		(1,202	)

Product revenue - net		36,935			10,995			57,038			19,213

Sales rebates are offered to distributors in China and the amounts are recorded as a reduction of revenue. Estimated rebates are determined based on contracted rates, sales volumes and level of distributor inventories.

The following table disaggregates net revenue by product for the three and six months ended June 30, 2021 and 2020:


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
	$		$		$		$
ZEJULA		23,366		7,446		35,972		13,791
Optune		9,535		3,549		16,665		5,422
QINLOCK		4,034		—		4,401		—

Product revenue - net		36,935		10,995		57,038		19,213

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Income Tax	6 Months Ended
Income Tax	Jun. 30, 2021
Income tax
Income tax	10. Income Tax No provision for income taxes has been required to be accrued because the Company and all of its subsidiaries are in cumulative loss positions for all the periods presented. The Company recorded a full valuation allowance against deferred tax assets of all its consolidated entities because all entities were in a cumulative loss position as of June 30, 2021 and December 31, 2020. No unrecognized tax benefits and related interest and penalties were recorded in any of the periods presented.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Other current liabilities

6 Months Ended

Jun. 30, 2021

Other current liabilities

Other current liabilities

11. Other current liabilities

Other current liabilities consist of the following:


	As of
	June 30, 2021		December 31, 2020
	$		$
Payroll		12,474		13,694
Professional service fee		9,610		3,128
Payables for purchase of property and equipment		1,720		788
Accrued rebate to distributors		22,416		7,067
Others (note (i))		15,705		5,519

Total		61,925		30,196

Note:

(i)	Others are mainly payables to employees for exercising the share-based compensations, tax payables and payables related to travel and business entertainment expenses.

Loss per share

6 Months Ended

Jun. 30, 2021

Loss per share

Loss per share

12. Loss per share

Basic and diluted net loss per share for each of the period presented are calculated as follows:


	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
	$			$			$			$
Numerator:
Net loss attributable to ordinary shareholders		(163,324	)		(80,629	)		(396,234	)		(128,617	)
Denominator:
Weighted average number of ordinary shares- basic and diluted		93,045,531			74,738,563			90,723,132			73,847,551

Product revenue - net		(1.76	)		(1.08	)		(4.37	)		(1.74	)

As a result of the Group’s net loss for the six months ended June 30, 2021 and 2020, share options and

non-vested

restricted shares outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive.


	As of
	June 30, 2021		June 30, 2020
Share options		8,629,440		9,808,561
Non-vested restricted shares		632,535		710,068

Related Party Transactions

6 Months Ended

Jun. 30, 2021

Related party transactions

Related party transactions

13. Related party transactions

The table below sets forth the major related party and the relationship with the Group as of June 30, 2021:


Company Name		Relationship with the Group
MEDx (Suzhou) Translational Medicine Co., Ltd.		Significant influence held by Samantha Du’s (Director, Chairwoman and Chief Executive Officer of the Company) immediate family

For the three and six months ended June 30, 2021, the Group incurred $104 and $207 research and d

evelopment

expense with MEDx (Suzhou) Translational Medicine Co., Ltd. for product research and development services, respectively. The Group incurred $129 and $184 research and development expense for the three and six months ended June 30, 2020, respectively. All of the transactions are carried out with normal business terms and are on arms’ length basis.

Share-based compensation

6 Months Ended

Jun. 30, 2021

Share-based compensation

Share-based compensation

14. Share-based compensation

Share options

On March 5, 2015, the Board of Directors of the Company approved an Equity Incentive Plan (the “2015 Plan”) which is administered by the Board of Directors. Under the 2015 Plan, the Board of Directors may grant options to purchase ordinary shares to management including officers, directors, employees and individual advisors who render services to the Group to purchase an aggregate of no more than 4,140,945 ordinary shares of the Group (“Option Pool”). Subsequently, the Board of Directors approved the increase in the Option Pool to 7,369,767 ordinary shares.

In connection with the completion of the initial public offering (the “IPO”), the Board of Directors approved the 2017 Equity Incentive Plan (the “2017 Plan”) and all equity-based awards subsequent to the IPO would be granted under the 2017 Plan.

For the six months ended June 30, 2020, the Group granted 960,878 share options to certain management, employees and individual advisors of the Group at the exercise price ranging from $44.94 to $82.13 per share under the 2017 Plan. These options granted have a contractual term of ten years and generally vest over a five- or

three-year

period, with 20% or 33.3% of the awards vesting beginning on the anniversary date one year after the grant date.

For the six months ended June 30, 2021, the Group granted 512,088 share options to certain management and employees of the Group at the exercise price ranging from $130.96 to $180.00 per share under the 2017 Plan. These options granted have a contractual term of ten years and generally vest over a five-year period, with 20% of the awards vesting beginning on the anniversary date one year after the grant date.

The weighted-average grant-date fair value of the options granted in the six months ended June 30, 2021 and 2020 were $81.37 and $33.51 per share, respectively. The Group recorded compensation expense related to the options of $12,776 and $10,355 for the six months ended June 30, 2021 and 2020, respectively, which were classified in the accompanying unaudited condensed consolidated statements of operations as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
	$		$		$		$
Selling, general and administrative		4,123		2,804		7,382		5,548
Research and development		3,104		2,630		5,394		4,807

Total		7,227		5,434		12,776		10,355

As of June 30, 2021, there was $97,837 of total unrecognized compensation expense related to unvested share opt

ons granted. That cost is expected to be recognized over a

weighted-average

period of 1.48 years which is determined based on the number of shares and unrecognized years.

Non-vested restricted shares

For the six months ended June 30, 2020, 50,000 ordinary shares were authorized for grant to the independent directors. The restricted shares will vest and be released from the restrictions in full on the first anniversary from the date of the agreement. Upon termination of the independent directors’ service with the Group for any reason, any shares that are outstanding and not yet vested will be immediately forfeited.

For the six months ended June 30, 2020, 45,000 ordinary shares were authorized for grant to certain management. One fifth of the restricted shares will vest and be released from the restrictions on each yearly anniversary from the date of the agreement. Upon termination of the certain management’s service with the Group for any reason, any shares that are outstanding and not yet vested will be immediately forfeited.

For the six months ended June 30, 2021, 19,260 ordinary shares were authorized for grant to the independent directors. The restricted shares will vest and be released from the restrictions in full on the first anniversary from the date of the agreement. Upon termination of the independent directors’ service with the Group for any reason, any shares that are outstanding and not yet vested will be immediately forfeited.

For the six months ended June 30, 2021, 203,575 ordinary shares were authorized for grant to certain management. One fifth of the restricted shares will vest and be released from the restrictions on each yearly anniversary from the date of the agreement. Upon termination of the certain management’s service with the Group for any reason, any shares that are outstanding and not yet vested will be immediately forfeited.

The Group measured the fair value of the

non-vested

restricted shares as of respective grant dates and recognized the amount as compensation expense over the deemed service period using a graded vesting attribution model on a straight-line basis.

As of June 30, 2021, there was $40,562 of total unrecognized compensation expense related to

non-vested

restricted shares. The Group recorded compensation expense related to the restricted shares of $4,774 and $3,072 for the six months ended June 30, 2021 and 2020, respectively, which were classified in the accompanying unaudited condensed consolidated statements of operations as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
	$		$		$		$
Selling, general and administrative		1,839		1,046		3,050		2,114
Research and development		1,166		484		1,724		958

Total		3,005		1,530		4,774		3,072

Licenses and collaborative arrangement	6 Months Ended
Licenses and collaborative arrangement	Jun. 30, 2021
Licenses And Collaborative Arrangement [Abstract]
Licenses and collaborative arrangement	1 5 . Licenses and collaborative arrangement The following is a description of the Group’s significant ongoing collaboration agreements for the three and six months ended June 30, 2021. License and collaboration agreement with GSK In September 2016, the Group entered into a collaboration, development and license agreement with Tesaro, Inc., a company later acquired by GSK, pursuant to which it obtained an exclusive sublicense under certain patents and know-how of GSK (including such patents and know-how licensed from Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., and AstraZeneca UK Limited) to develop, manufacture and commercialize GSK’s proprietary PARP inhibitor, niraparib, in China, Hong Kong and Macau for the diagnosis and prevention of any human diseases or conditions (other than prostate cancer). The Group also obtained the right of first negotiation to obtain a license to develop and commercialize certain follow-on compounds of niraparib being developed by GSK in the licensed territory. Under the agreement, the Group agreed not to research, develop or commercialize certain competing products, and the Group also granted GSK the right of first refusal to license certain immuno-oncology assets developed by the Group. In February 2018, the Group entered into an amendment with GSK that eliminated GSK’s option to co-market niraparib in the licensed territory. Under the terms of the agreement, the Group made an upfront payment of $15,000 and one milestone payment of $1,000, and accrued one development milestone payment of $3,500 to GSK. On top of those, if the Group achieves other specified regulatory, development and commercialization milestones, the Group may be additionally required to pay further milestone payments up to $36,000 to GSK. In addition, if the Group successfully develops and commercializes the licensed products, the Group will pay GSK tiered royalties on the net sales of the licensed products, until the later of the expiration of the last-to-expire licensed patent covering the licensed product, the expiration of regulatory exclusivity for the licensed product, or the tenth anniversary of the first commercial sale of the licensed product, in each case on a product-by-product and region-by-region basis. The Group has the right to terminate this agreement at any time by providing written notice of termination to GSK. License and collaboration agreements with MacroGenics Inc. (“MacroGenics”) In November 2018, the Group entered into a collaboration agreement with MacroGenics, pursuant to which it obtained an exclusive license under certain patents and know-how of MacroGenics to develop and commercialize margetuximab, tebotelimab (MGD-013) and an undisclosed multi-specific TRIDENT molecule in pre-clinical development, each as an active ingredient in all human fields of use, except to the extent limited by any applicable third party agreement of MacroGenics in Greater China. Under the terms of the agreement, the Group paid an upfront license fee of $25,000 and two milestone payments in total of $4,000 to MacroGenics. The Group also agreed to pay certain development and regulatory-based milestone payments up to an aggregate of $136,000, and tiered royalties at percentage rates for net sales of Margetuximab, tebotelimab and TRIDENT molecule in the territory. The Group has the right to terminate this agreement at any time by providing written notice of termination to MacroGenics. In June 2021, the Group entered into a collaboration and license agreement with MacroGenics, pursuant to which the Group and MacroGenics made four collaboration programs involving up to four immuno-oncology molecules. The first collaboration program covers a lead research molecule that incorporates MacroGenics’ DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors. The second collaboration program will cover a target to be designated by MacroGenics. For both molecules, the Group received commercial rights in Greater China, Japan, and Korea and MacroGenics received commercial rights in all other territories. For the lead molecule, the Group receives an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. The Group also obtained exclusive, global licenses from MacroGenics to develop, manufacture and commercialize two additional molecules. For these four programs, each company will contribute intellectual property to generate either CD3- or CD47-based bispecific antibodies. Under the terms of the agreement, the Group accrued an upfront payment of $25,000 to MacroGenics. In addition, MacroGenics is also eligible to receive up to $1,386,000 in potential development, regulatory and commercial milestone payments for the four programs. If products from the collaboration are commercialized, MacroGenics would also receive royalties on annual net sales in the Group’s territories. Pursuant to the collaboration and license agreement, the Group also agreed to make an equity investment of $30,000 in MacroGenics’ common stock at $31.30 per share (see Note 18). The Group has the right to terminate this agreement at any time by providing written notice of termination to MacroGenics. License and collaboration agreement with Deciphera In June 2019, the Group entered into a license agreement with Deciphera, pursuant to which it obtained an exc l usive license under certain patents and know-how of Deciphera to develop and commercialize products containing ripretinib in the field of the prevention, prophylaxis, treatment, cure or amelioration of any disease or medical condition in humans in Greater China. Under the terms of the agreement, the Group paid Deciphera an upfront license fee of $20,000 and three milestone payments of $12,000. The Group also agreed to pay certain additional development, regulatory and commercial milestone payments up to an aggregate of $173,000, and certain tiered royalties (from low-to-high teens on a percentage basis and subject to certain reductions) based on the net sales of the licensed products in the territory. The Group has the right to terminate this agreement at any time by providing written notice of termination to Deciphera. License agreements with Turning Point Therapeutics Inc (“Turning Point”) In July 2020, the Group entered into an exclusive license agreement with Turning Point pursuant to which Turning Point exclusively licensed to the Group the rights to develop and commercialize products containing repotrectinib as an active ingredient in all human therapeutic indications, in Greater China. Under the terms of the agreements, the Group paid an upfront payment of $25,000 and one milestone payment of $2,000, and accrued two milestone payments totaling $3,000 to Turning Point. Turning Point is also eligible to receive up to $146,000 in development, regulatory and sales milestones. Turning Point will also be eligible to receive certain tiered royalties (from mid-to-high teens on a percentage basis and subject to certain reductions) based on annual net sales of repotrectinib in Greater China. The Group has the right to terminate this agreement at any time by providing written notice of termination to Turning Point. In January 2021, the Group entered into a license agreement with Turning Point, which expanded their collaboration. Under the terms of the new agreement, the Group obtained exclusive rights to develop and commercialize TPX-0022, Turning Point’s MET, SRC and CSF1R inhibitor, in Greater China. The Group paid an upfront license fee in the amount of $25,000 to Turning Point. The Group also agreed to pay certain development, regulatory and commercial milestone payments up to an aggregate of $336,000. Turning Point will also be eligible to receive certain tiered royalties (from mid-teens to low-twenties on a percentage basis and subject to certain reductions) based on annual net sales of TPX-0022 in Greater China. In addition, Turning Point will have the right of first negotiation to develop and commercialize an oncology product candidate discovered by the Group. License and collaboration agreement with Five Prime Therapeutics, Inc. (“Five Prime”) In December 2017, the Group entered into a license and collaboration agreement with Five Prime (a company later acquired by Amgen Inc.), pursuant to which it obtained an exclusive license under certain patents and know-how of Five Prime to develop and commercialize products containing Five Prime’s proprietary afucosylated FGFR2b antibody known as bemarituzumab (FPA144) as an active ingredient in the treatment or prevention of any disease or condition in humans in Greater China. Under the terms of the agreement, the Group made an upfront payment of $5,000 and a milestone payment of $2,000 to Five Prime. Additionally, the Group also agreed to pay further development and regulatory milestone payments of up to an aggregate of $37,000 to Five Prime and certain tiered royalties (from high-teens to low-twenties on a percentage basis and subject to certain reductions) based on the number of patients the Group enrolls in the bemarituzumab study. The Group has the right to terminate this agreement at any time by providing written notice of termination to Five Prime. License agreement with Cullinan Pearl Corp. (“Cullinan”) In December 2020, the Group entered into a license agreement with Cullinan, a subsidiary of Cullinan Management, Inc., formerly Cullinan Oncology, LLC, pursuant to which it obtained an exclusive license under certain patents and know-how of Cullinan to dev e lop, manufacture and commercialize products containing CLN-081 as an active ingredient in all uses in humans and animals in Greater China. Under the terms of the agreement, the Group paid an upfront payment of $20,000 to Cullinan. Cullinan is also eligible to receive up to $211,000 in development, regulatory and sales-based milestone payments. Cullinan is also eligible to receive certain tiered royalties (from high-single-digit to low-teen tiered royalties on a percentage basis and subject to certain reductions) based on annual net sales of CLN-081 in Greater China. The Group has the right to terminate this agreement at any time by providing written notice of termination to Cullinan. License agreement with Takeda Pharmaceutical Company Limited (“Takeda”) In December 2020, the Group entered into an exclusive license agreement with Takeda. Under the terms of the license agreement, Takeda exclusively licensed to the Group the right to exploit products in the licensed field during the term. Under the terms of the agreement, the Group paid an upfront payment of $6,000 to Takeda. Takeda is also eligible to receive up to $481,500 in development, regulatory and sales-based milestone payments. Takeda is also eligible to receive certain tiered royalties (from high-single-digit to low-teen tiered royalties on a percentage basis and subject to certain reductions) based on net sales of each product sold by selling party during each year of the applicable royalty term. The Group has the right to terminate this agreement at any time by providing written notice of termination to Takeda. Collaboration and license agreement with argenx BV (“argenx”) In January 2021, the Group entered into a collaboration and license agreement with argenx. The Group received an exclusive license to develop and commercialize products containing argenx’s proprietary antibody fragment, known as efgartigimod, in Greater China. The Group is responsible for the development of the licensed compound and licensed product and will have the right to commercialize such licensed product in the territory. Pursuant to the collaboration and license agreement, a share issuance agreement was entered into between the Group and argenx. As the upfront payment to argenx, the Group issued 568,182 ordinary shares of the Company to argenx with par value $0.00006 per share on the closing date of January 13, 2021. In determining the fair value of the ordinary shares at closing, the Company considered the closing price of the ordinary shares on the closing date and included a lack of marketability discount because the shares are subject to certain restrictions. The fair value of the shares on the closing date was determined to be $62,250 in the aggregate. The Group recorded this upfront payment in research and development expenses. In addition, the Group made a non-creditable, non-refundable development cost-sharing payment of $75,000 to argenx. Argenx is also eligible to receive a cash payment of $25,000 upon the first regulatory approval of a licensed product by the U.S. Food and Drug Administration for myasthenia gravis and tiered royalties (from mid-teen to low-twenties on a percentage basis and subject to certain reductions) based on annual net sales of all licensed product in the territory. Collaboration and license agreement with Mirati Therapeutics, Inc. (“Mirati”) In May 2021, the Group entered into a collaboration and license agreement with Mirati. The Group obtained the right to research, develop, manufacture and exclusively commercialize adagrasib in Greater China. The Group will support accelerated enrollment in key global, registration-enabling clinical trials of adagrasib in patients with cancer who have a KRASG12C mutation. Mirati has an option to co-commercialize in Greater China and retains full and exclusive rights to adagrasib in all countries outside of Greater China. Under the terms of the agreement, the Group accrued an upfront payment of $65,000 to Mirati. Mirati is also eligible to receive up to $273,000 in development, regulatory and sales-based milestone payments. Mirati is also eligible to receive high-teen- to low-twenties-percent tiered royalties based on annual net sales of adagrasib in Greater China. The Group has the right to terminate this agreement at any time by providing written notice of termination to Mirati. Full details of the licenses and collaborative arrangements are included in our Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on March 1, 2021 and this Quarterly Report on Form 10-Q. As noted above, the Group has entered into various license and collaboration agreements with third party licensors to develop and commercialize product candidates. Based on the terms of these agreements, the Group is contingently obligated to make additional material payments upon the achievement of certain contractually defined milestones. Based on management’s evaluation of the progress of each project noted above, the licensors will be eligible to receive from the Group up to an aggregate of approximately $ 4,541,502 in future milestone payments upon the achievement of contractually specified development milestones, such as regulatory approval for the product candidates, which may be before the Group has commercialized the product or received any revenue from sales of such product candidate, which may never occur.

Restricted Net Assets	6 Months Ended
Restricted Net Assets	Jun. 30, 2021
Restricted net assets
Restricted net assets	1 6 . Restricted net assets The Group’s ability to pay dividends may depend on the Group receiving distributions of funds from its Chinese subsidiary. Relevant PRC statutory laws and regulations permit payments of dividends by the Group’s Chinese subsidiary only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP differ from those reflected in the statutory financial statements of the Group’s PRC subsidiary. In accordance with the Company Law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise’s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise’s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Group’s Chinese subsidiary was established as domestic invested enterprise and therefore is subject to the above-mentioned restrictions on distributable profits. During the three and six months ended June 30, 2021 and 2020, no appropriation to statutory reserves was made because the Group’s Chinese subsidiary had substantial losses during such periods. As a result of these PRC laws and regulations subject to the restrictions discussed above that require annual appropriations of 10% of after-tax income to be set aside, prior to payment of dividends, as general reserve fund, the Group’s Chinese subsidiary is restricted in their ability to transfer a portion of their net assets to the Group. Foreign exchange and other regulation s in China may further restrict the Group’s Chinese subsidiary from transferring funds to the Group in the form of dividends, loans and advances. As of June 30, 2021 and December 31, 2020, amounts restricted are the paid-in capital of the Group’s Chinese subsidiaries, which amounted to $306,010 and $205,858, respectively.

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	1 7 . Commitments and Contingencies (a) Purchase commitments As of June 30, 2021, the Group’s commitments related to purchase of property and equipment contracted but not yet reflected in the unaudited condensed consolidated financial statement were $28,191 and $49 which are expected to be incurred within one year and within one to two years, respectively. (b) Contingencies The Group is a party to or assignee of license and collaboration agreements that may require it to make future payments relating to milestone fees and royalties on future sales of licensed products (Note 1 5 ).

Subsequent Event	6 Months Ended
Subsequent Event	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Event	1 8 . Subsequent Event In July 2021, the Group made an equity investment in MacroGenics in a private placement with total contributions amounting to $30,000 and obtained 958,467 newly issued common shares of MacroGenics at $31.30 per share. In July and August 2021, the Group granted 11,701 share options to certain management and employees of the Group at exercise prices ranging from $144.61 to $178.37 per share under the 2017 Plan. These options granted have a contractual term of ten years and generally vest over a five-year period, with 20% of the awards vesting beginning on the anniversary date one year after the grant date. In July and August 2021, 32,341 ordinary shares were authorized for grant to certain management and employees of the Group. One-fifth of the restricted shares will vest and be released from the restrictions on each yearly anniversary from the date of the agreement. Upon termination of the certain management’s service with the Group for any reason, any shares that are outstanding and not yet vested will be immediately forfeited. In August 2021, the Group entered into a global discovery, development and commercialization collaboration with Schrödinger, Inc., or Schrödinger, pursuant to which the parties will jointly conduct a research program focused on a novel DNA damage repair program in the area of oncology. Following the selection of a development candidate, the Group will assume primary responsibility for global development, manufacturing and commercialization of the program.

Basis of presentation and consolidation and significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of presentation	(a) Basis of presentation The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company’s financial position, results of operations, and cash flows in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company’s unaudited condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December 31, 2020 condensed consolidated balance sheets data were derived from audited financial statements, but do not include all disclosures required by U.S. GAAP. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.
Principles of consolidation	(b) Principles of consolidation The unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All intercompany transactions and balances among the Company and its subsidiaries are eliminated upon consolidation.
Use of estimates	(c) Use of estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating the current expected credit losses for financial assets, assessing the impairment of long-lived assets, discount rate of operating lease liabilities, revenue recognition, allocation of the research and development service expenses to the appropriate financial reporting period based on the progress of the research and development projects, share-based compensation expenses, recoverability of deferred tax assets and a lack of marketability discount of the ordinary shares issued in connection with collaboration and license arrangement (Note 15 ). Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.
Fair value measurements	(d) Fair value measurements The Group applies ASC topic 820 (“ASC 820”), Fair Value Measurements and Disclosures , in measuring fair value. ASC 820 defines fair value, establishes a framework for measuring fair value and requires disclosures to be provided on fair value measurement. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - Include other inputs that are directly or indirectly observable in the marketplace. Level 3 - Unobservable inputs which are supported by little or no market activity. ASC 820 describes three main approaches to measur e the fair value of assets and liabilities: (1) market approach; (2) income approach and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset. Financial instruments of the Group primarily include cash, cash equivalents and restricted cash, short-term investments, accounts receivable, prepayments and other current assets, accounts payable and other payables. As of June 30, 2021 and December 31, 2020, the carrying values of cash and cash equivalents, short-term investments, accounts receivable, prepayments and other current assets, accounts payable and other payable approximated their fair values due to the short-term maturity of these instruments, and the carrying value of restricted cash approximates its fair value based on the nature of the assessment of the ability to recover these amounts.
Recent accounting pronouncements	(e) Recent accounting pronouncements Adopted Accounting Standards In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . This update simplifies the accounting for income taxes as part of the FASB’s overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC 740, Income taxes , and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in fiscal years beginning after December 15, 2020, and interim periods therein, and early adoption is permitted. Certain amendments in this update should be applied retrospectively or modified retrospectively, all other amendments should be applied prospectively. The Group adopted this standard on January 1, 2021. There was no material impact to the Group’s financial position or results of operations upon adoption.
Significant accounting policies	(f) Significant accounting policies For a more complete discussion of the Company’s significant accounting policies and other information, the unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Cash and cash equivalents (Tables)

6 Months Ended

Jun. 30, 2021

Cash and Cash Equivalents [Abstract]

Summary of cash and cash equivalents


	As of
	June 30, 2021		December 31, 2020
	$		$
Cash at bank and in hand		1,465,757		441,283
Cash equivalents (note (i))		300,816		833

		1,766,573		442,116

Denominated in:
US$		907,662		297,813
RMB (note (ii))		36,222		23,898
Hong Kong dollar (“HK$”)		822,182		119,695
Australian dollar (“A$”)		471		710
Taiwan dollar (“TW$”)		36		—

		1,766,573		442,116

Note:

(i)	Cash equivalents represent short-term and highly liquid investments in a money market fund.

(ii)	Certain cash and bank balances denominated in RMB were deposited with banks in China. The conversion of these RMB denominated balances into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the government of the People’s Republic of China (“PRC”).

Inventories (Tables)

6 Months Ended

Jun. 30, 2021

Inventories

Schedule of inventory


	As of
	June 30, 2021		December 31, 2020
	$		$
Finished goods		4,477		3,041
Raw materials		6,269		10,103
Work in process		368		—

Inventories		11,114		13,144

Property and Equipment, net (Tables)

6 Months Ended

Jun. 30, 2021

Property and equipment, net

Schedule of property and equipment


	As of
	June 30, 2021			December 31, 2020
	$			$
Office equipment		444			430
Electronic equipment		3,269			2,646
Vehicle		218			143
Laboratory equipment		13,384			11,933
Manufacturing equipment		12,838			12,198
Leasehold improvements		9,889			9,641
Construction in progress		4,699			2,423

		44,741			39,414
Less: accumulated depreciation		(13,099	)		(10,252	)

Property and equipment, net		31,642			29,162

Revenue (Tables)

6 Months Ended

Jun. 30, 2021

Revenue

Schedule of net product sales


	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
	$			$			$			$
Product revenue - gross		41,380			11,478			87,935			20,415
Less: Rebate and sales return		(4,445	)		(483	)		(30,897	)		(1,202	)

Product revenue - net		36,935			10,995			57,038			19,213

Schedule of disaggregation of net revenue

The following table disaggregates net revenue by product for the three and six months ended June 30, 2021 and 2020:


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
	$		$		$		$
ZEJULA		23,366		7,446		35,972		13,791
Optune		9,535		3,549		16,665		5,422
QINLOCK		4,034		—		4,401		—

Product revenue - net		36,935		10,995		57,038		19,213

Other current liabilities (Tables)

6 Months Ended

Jun. 30, 2021

Other current liabilities

Schedule of other current liabilities

11. Other current liabilities

Other current liabilities consist of the following:


	As of
	June 30, 2021		December 31, 2020
	$		$
Payroll		12,474		13,694
Professional service fee		9,610		3,128
Payables for purchase of property and equipment		1,720		788
Accrued rebate to distributors		22,416		7,067
Others (note (i))		15,705		5,519

Total		61,925		30,196

Note:

(i)	Others are mainly payables to employees for exercising the share-based compensations, tax payables and payables related to travel and business entertainment expenses.

Loss per share (Tables)

6 Months Ended

Jun. 30, 2021

Loss per share

Summary of basic and diluted net loss per share

Basic and diluted net loss per share for each of the period presented are calculated as follows:


	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
	$			$			$			$
Numerator:
Net loss attributable to ordinary shareholders		(163,324	)		(80,629	)		(396,234	)		(128,617	)
Denominator:
Weighted average number of ordinary shares- basic and diluted		93,045,531			74,738,563			90,723,132			73,847,551

Product revenue - net		(1.76	)		(1.08	)		(4.37	)		(1.74	)

Summary of anti-dilutive excluded from the calculation of diluted loss per share

As a result of the Group’s net loss for the six months ended June 30, 2021 and 2020, share options and

non-vested

restricted shares outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive.


	As of
	June 30, 2021		June 30, 2020
Share options		8,629,440		9,808,561
Non-vested restricted shares		632,535		710,068

Related Party Transactions (Tables)

6 Months Ended

Jun. 30, 2021

Related party transactions

Schedule of Major Related Party and Relationship

The table below sets forth the major related party and the relationship with the Group as of June 30, 2021:


Company Name		Relationship with the Group
MEDx (Suzhou) Translational Medicine Co., Ltd.		Significant influence held by Samantha Du’s (Director, Chairwoman and Chief Executive Officer of the Company) immediate family

Share-based compensation (Tables)

6 Months Ended

Jun. 30, 2021

Allocation of compensation expense related to options


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
	$		$		$		$
Selling, general and administrative		4,123		2,804		7,382		5,548
Research and development		3,104		2,630		5,394		4,807

Total		7,227		5,434		12,776		10,355

Allocation of compensation expense related to restricted shares

As of June 30, 2021, there was $40,562 of total unrecognized compensation expense related to

non-vested


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
	$		$		$		$
Selling, general and administrative		1,839		1,046		3,050		2,114
Research and development		1,166		484		1,724		958

Total		3,005		1,530		4,774		3,072

Cash and cash equivalents - Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Cash And Cash Equivalents [Line Items]
Cash at bank and in hand	$ 1,465,757	$ 441,283
Cash equivalents	300,816	833
Cash and cash equivalents	1,766,573	442,116	$ 258,604
Denominated in US$
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents	907,662	297,813
Denominated in RMB
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents	36,222	23,898
Denominated in Hong Kong dollar
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents	822,182	119,695
Denominated in Australia dollar
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents	471	$ 710
Denominated in Taiwan dollar
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents	$ 36

Restricted cash, non-current - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Restricted Cash [Abstract]
Restricted cash, non-current	$ 743	$ 743	$ 510

Short-term investments (Details) - USD ($) $ in Thousands	6 Months Ended
Short-term investments (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Schedule Of Available For Sale Securities [Line Items]
Short-term investments	$ 0	$ 744,676
Investments, allowance for credit losses		$ 0
Maturities of Time Deposits, Description	time deposits with original maturities between three months and one year.
Minimum
Schedule Of Available For Sale Securities [Line Items]
Time deposits, Maturity period	3 months
Maximum
Schedule Of Available For Sale Securities [Line Items]
Time deposits, Maturity period	1 year

Inventories - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Inventory [Line Items]
Inventory write-down	$ 277	$ 7	$ 290	$ 7
Inventory balance	$ 11,114		$ 11,114		$ 13,144

Inventories - Schedule of inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventories
Finished goods	$ 4,477	$ 3,041
Raw materials	6,269	10,103
Work in process	368	0
Inventories	$ 11,114	$ 13,144

Investments in Equity Investees - Additional Information (Details) ¥ in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2020	Jun. 30, 2017 CNY (¥) item
Equity And Cost Method Investments
Share of gain (loss) from equity method investment	$ (403)	$ (269)	$ (208)	$ (406)
JING
Equity And Cost Method Investments
Share of gain (loss) from equity method investment	403	$ 269	671	$ 406
Equity method investment, gain on disposal	$ 0		$ 463
Number of third-parties \| item						3
Capital contribution commitment \| ¥						¥ 26,250
Percentage of equity interest	18.00%		18.00%		20.00%

Property and Equipment, net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property Plant And Equipment
Property and equipment, gross	$ 44,741	$ 39,414
Less: accumulated depreciation	(13,099)	(10,252)
Property and equipment, net	31,642	29,162
Office Equipment
Property Plant And Equipment
Property and equipment, gross	444	430
Electronic Equipment
Property Plant And Equipment
Property and equipment, gross	3,269	2,646
Vehicle
Property Plant And Equipment
Property and equipment, gross	218	143
Laboratory Equipment
Property Plant And Equipment
Property and equipment, gross	13,384	11,933
Manufacturing Equipment
Property Plant And Equipment
Property and equipment, gross	12,838	12,198
Leasehold Improvements
Property Plant And Equipment
Property and equipment, gross	9,889	9,641
Construction in Progress
Property Plant And Equipment
Property and equipment, gross	$ 4,699	$ 2,423

Property and Equipment, net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Property and equipment, net
Depreciation expenses	$ 1,407	$ 968	$ 2,747	$ 1,974

Revenue - (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Revenue - (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue
Product revenue - gross	$ 41,380	$ 11,478	$ 87,935	$ 20,415
Less: Rebate and sales return	(4,445)	(483)	(30,897)	(1,202)
Product revenue - net	$ 36,935	$ 10,995	$ 57,038	$ 19,213

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Revenue - Disaggregation of net revenue by product (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue
Product revenue - net	$ 36,935,000	$ 10,995,000	$ 57,038,000	$ 19,213,000
ZEJULA
Disaggregation of Revenue
Product revenue - net	23,366,000	7,446,000	35,972,000	13,791,000
Optune
Disaggregation of Revenue
Product revenue - net	9,535,000	$ 3,549,000	16,665,000	$ 5,422,000
QINLOCK
Disaggregation of Revenue
Product revenue - net	$ 4,034		$ 4,401,000

- Definition

+ References

+ Details

Income Tax - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Income Tax Disclosure [Line Items]
Unrecognized tax benefits	$ 0	$ 0
Unrecognized tax benefits, interest and penalties	$ 0	$ 0

Other current liabilities - Schedule of Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Other current liabilities
Payroll	$ 12,474	$ 13,694
Professional service fee	9,610	3,128
Payables for purchase of property and equipment	1,720	788
Accrued rebate to distributors	22,416	7,067
Others	15,705	5,519
Total	$ 61,925	$ 30,196

Loss per share - Summary of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator:
Net loss attributable to ordinary shareholders	$ (163,324)	$ (80,629)	$ (396,234)	$ (128,617)
Denominator:
Weighted average number of ordinary shares- basic and diluted	93,045,531	74,738,563	90,723,132	73,847,551
Product revenue -net	$ (1.76)	$ (1.08)	$ (4.37)	$ (1.74)

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

+ Details

Loss per share - Summary of Anti-Dilutive Shares Excluded from Calculation of Diluted Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted loss per share	8,629,440	9,808,561
Non-Vested Restricted Shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted loss per share	632,535	710,068

Related party transactions - Schedule of Major Related Party and Relationship (Details)	6 Months Ended
	Jun. 30, 2021
MEDx (Suzhou) Translational Medicine Co., Ltd.
Related Party Transaction [Line Items]
Relationship with the Group	Significant influence held by Samantha Du’s (Director, Chairwoman and Chief Executive Officer of the Company) immediate family

- Definition

A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.

+ References + Details

Related party transactions - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Research and development \| MEDx (Suzhou) Translational Medicine Co., Ltd.
Related Party Transaction [Line Items]
Transactions between its related party	$ 104	$ 129	$ 207	$ 184

Share-based compensation - Share Options - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Mar. 05, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares authorized	7,369,767		7,369,767		4,140,945
Weighted-average grant-date fair value of options granted			$ 81.37	$ 33.51
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Compensation expense	$ 7,227	$ 5,434	$ 12,776	$ 10,355
Unrecognized compensation expense related to unvested share options granted	$ 97,837		$ 97,837
Recognized over a weighted-average period			1 year 5 months 23 days
Management, Employees and Individual Advisors \| Two Thousand Seventeen Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted			512,088	960,878
Exercise price of options			$ 180.00
Options granted contractual term			10 years	10 years
Vesting period			5 years
Management, Employees and Individual Advisors \| Vesting anniversary year after the grant date \| Two Thousand Seventeen Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option vesting percentage			20.00%
Management, Employees and Individual Advisors \| Minimum \| Two Thousand Seventeen Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of options				$ 44.94
Vesting period				3 years
Management, Employees and Individual Advisors \| Minimum \| Vesting anniversary year after the grant date \| Two Thousand Seventeen Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option vesting percentage				20.00%
Management, Employees and Individual Advisors \| Maximum \| Two Thousand Seventeen Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of options				$ 82.13
Vesting period			5 years
Management, Employees and Individual Advisors \| Maximum \| Vesting anniversary year after the grant date \| Two Thousand Seventeen Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option vesting percentage				33.30%

Share-based compensation - Allocation of Compensation Expense Related to Option (Details) - Stock Options - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Compensation expense	$ 7,227	$ 5,434	$ 12,776	$ 10,355
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Compensation expense	4,123	2,804	7,382	5,548
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Compensation expense	$ 3,104	$ 2,630	$ 5,394	$ 4,807

Share-based compensation - Non-vested Restricted Shares - Additional Information (Details) - Non-Vested Restricted Shares - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized share-based compensation	$ 40,562		$ 40,562
Compensation expense	$ 3,005	$ 1,530	$ 4,774	$ 3,072
Independent Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted			19,260	50,000
Management
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted			203,575	45,000
Management \| Each yearly anniversary from the date of the agreement
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option vesting percentage			20.00%	20.00%

Share-based compensation - Allocation of Compensation Expense Related to Restricted Shares (Details) - Non-Vested Restricted Shares - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Compensation expense	$ 3,005	$ 1,530	$ 4,774	$ 3,072
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Compensation expense	1,839	1,046	3,050	2,114
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Compensation expense	$ 1,166	$ 484	$ 1,724	$ 958

Licenses and collaborative arrangement (Details) $ / shares in Units, $ in Thousands		1 Months Ended				3 Months Ended	6 Months Ended
	Jan. 13, 2021 $ / shares shares	Jan. 31, 2021 USD ($)	Dec. 31, 2020 $ / shares	Jun. 30, 2019 Milestone	Dec. 31, 2017 Investors	Mar. 31, 2021 USD ($)	Jun. 30, 2021 USD ($) Milestone Molecules programs $ / shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock par value \| $ / shares			$ 0.00006				$ 0.00006
Issuance of ordinary shares in connection with collaboration and license arrangement						$ 62,250
Number of molecules \| Molecules							2
Number of programs \| programs							4
Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments to be made upon achievement							$ 4,541,502
Five Prime
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement date					2017-12
Payment of upfront fees							5,000
Number of milestone payments \| Investors					1
Milestone payments							2,000
Five Prime \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional milestone payments							37,000
Deciphera Pharmaceuticals LLC
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement date				2019-06
Payment of upfront fees							20,000
Milestone payment accrued						$ 12,000
Number of milestone payments \| Milestone				3
Deciphera Pharmaceuticals LLC \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional milestone payments							173,000
Argenx BV
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement date		2021-01
Development cost-sharing payment							75,000
Issuance of ordinary shares in connection with collaboration and license arrangement, Shares \| shares	568,182
Common stock par value \| $ / shares	$ 0.00006
Issuance of ordinary shares in connection with collaboration and license arrangement							62,250
Future cash payment							25,000
GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of upfront fees							15,000
Milestone payment accrued							$ 3,500
Number of milestone payments Accrued \| Milestone							1
Number of milestone payments \| Milestone							1,000,000
Milestone payments							$ 1,000
Additional milestone payments							36,000,000
ZLAB Turning Point Therapeutics Inc
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment accrued							$ 3,000
Number of milestone payments Accrued \| Milestone							2
Number of milestone payments \| Milestone							1
Milestone payments							$ 2,000
Mirati Therapeutics Inc
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of upfront fees for license agreement, accrued							65,000
Future milestone payments to be made upon achievement							$ 273,000
Mirati Therapeutics Inc \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of tiered royalties on annual net sales							20.00%
Mirati Therapeutics Inc \| Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of tiered royalties on annual net sales							0.00%
MacroGenics
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of upfront fees							$ 25,000
Payment of upfront fees for license agreement, accrued							$ 25,000
Number of milestone payments \| Milestone							2
Milestone payments							$ 4,000
Additional milestone payments							136,000
Future milestone payments to be made upon achievement							1,386,000
MacroGenics \| Collaboration and License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Equity Method Investments							$ 30,000
Issue price per share \| $ / shares							$ 31.30
Turning Point Therapeutics Inc
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement date		2021-01					2020-07
Payment of upfront fees		$ 25,000					$ 25,000
Turning Point Therapeutics Inc \| Potential Development Regulatory and Sales Based Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional milestone payments		$ 336,000
Future milestone payments to be made upon achievement							146,000
Cullinan Pearl Corp
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement date			2020-12
Payment of upfront fees							20,000
Cullinan Pearl Corp \| Potential Development Regulatory and Sales Based Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments to be made upon achievement							211,000
Takeda Pharmaceutical Company Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement date			2020-12
Payment of upfront fees							6,000
Takeda Pharmaceutical Company Limited \| Potential Development Regulatory and Sales Based Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments to be made upon achievement							$ 481,500

Restricted Net Assets (Details) - PRC - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Restricted net assets
Minimum required percentage of statutory reserves	10.00%	10.00%
Percentage of statutory reserves to respective registered capital	50.00%	50.00%
Statutory reserves	$ 0	$ 0
Restricted amount by subsidiaries	$ 306,010	$ 306,010	$ 205,858

Commitments and Contingencies (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Property and Equipment
Loss Contingencies [Line Items]
Purchase obligation	$ 28,191	$ 49

Subsequent Event (Details) $ / shares in Units, $ in Thousands	1 Months Ended
	Aug. 09, 2021 USD ($) $ / shares shares
Two Thousand Seventeen Equity Incentive Plan \| Management and Employees
Subsequent Event [Line Items]
Options granted contractual term	5 years
Subsequent Event \| MacroGenics
Subsequent Event [Line Items]
Issue price per share \| $ / shares	$ 31.30
Equity Method Investments \| $	$ 30,000
Stock Issued During Period, Shares, Acquisitions	958,467
Subsequent Event \| Management and Employees
Subsequent Event [Line Items]
Number of shares authorized for grant	32,341
Subsequent Event \| Management and Employees \| Restricted Shares
Subsequent Event [Line Items]
Shares vested	0.2
Subsequent Event \| Two Thousand Seventeen Equity Incentive Plan \| Management and Employees
Subsequent Event [Line Items]
Options granted	11,701
Options granted contractual term	10 years
Subsequent Event \| Two Thousand Seventeen Equity Incentive Plan \| Management and Employees \| Minimum
Subsequent Event [Line Items]
Exercise price of options \| $ / shares	$ 144.61
Subsequent Event \| Two Thousand Seventeen Equity Incentive Plan \| Management and Employees \| Maximum
Subsequent Event [Line Items]
Exercise price of options \| $ / shares	$ 178.37
Subsequent Event \| Two Thousand Seventeen Equity Incentive Plan \| Management and Employees \| Vesting anniversary year after the grant date
Subsequent Event [Line Items]
Vesting percentage	20.00%